Does Atorvastatin Affect Androgen Levels in Men in the Era of Very-low LDL Targeting Therapy?

Abstract

Background: An adequate pool of free intracellular cholesterol is essential for steroidogenesis in gonads and LDL is the major source of cholesterol used in this pathway. Effect of peripheral LDL on the synthesis of steroids is dose dependent and although LDL levels around 100 mg/dl is demonstrated to be safe in terms of steroidogenesis, effect of LDL levels <70 mg/dl with higher doses of statins on steroidogenesis remains controversial.

Material and Methods: Androgen and gonadotropin levels are prospectively evaluated at baseline and after 12 weeks of treatment in 77 male coronary heart disease patients receiving high doses of atorvastatin (40–80 mg daily) targeting serum LDL levels <70 mg/dl and in 83 male coronary heart disease patients receiving regular doses of atorvastatin (10–20 mg daily) targeting serum LDL levels <100 mg/dl.

Results: At the end of the study, mean LDL levels of the high and regular dose atorvastatin groups were 77±9 mg/dl and 98±10 mg/dl respectively. After twelve weeks of treatment, there were no significant alterations in serum total testosterone, free testosterone, sex hormone binding globulin, luteinizing hormone and follicle stimulating hormone levels between two groups.

Conclusion: High dose atorvastatin in order to reach serum LDL levels around 70 mg/dl seems to be as safe as regular doses in order to reach serum LDL levels around 100 mg/dl, in terms of gonadal steroidogenesis in men with coronary heart disease.

Key words

statins - Coronary Artery Disease - androgens

References

• 1 ATP III final report . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.  Circulation. 2002;  106 3143-3421
• 2 Azhar S, Tsai L, Medicherla S, Chandrasekher Y, Giudice L, Reaven E. Human granulosa cells use high density lipoprotein cholesterol for steroidogenesis.  J Clin Endocrinol Metab. 1998;  83 983-991
• 3 Azzarito C, Boiardi L, Zini M, Agosti A, Dotti C, Biagi R, Portioli I. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients.  Metabolism. 1992;  41 148-153
• 4 Bernini GP, Argenio GF, Gasperi M, Vivaldi MS, Franchi F, Salvetti A. Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients.  J Endocrinol Invest. 1994;  17 227-233
• 5 Böhm M, Herrmann W, Wassmann S, Laufs U, Nickenig G. Does statin therapy influence steroid hormone synthesis?.  Z Kardiol. 2004;  93 43-48
• 6 Carr BR, Parker  Jr  CR, Ohashi M, MacDonald PC, Simpson ER. Regulation of human fetal testicular secretion of testosterone: low-density lipoprotein – cholesterol and cholesterol synthesized de novo as steroid precursor.  Am J Obstet Gynecol. 1983;  146 241-247
• 7 Dobs AS, Miller S, Neri G, Weiss S, Tate AC, Shapiro DR, Musliner TA. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients.  Metabolism. 2000;  49 115-121
• 8 Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme-A reductase inhibitor.  Metabolism. 1993;  42 1146-1152
• 9 Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, Wu M, Mitchel Y, Illingworth RD. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.  Metabolism. 2000;  49 1234-1238
• 10 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
• 11 Grundy SM, Cleeman JI, Merz CN, Brewer  Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.  Circulation. 2004;  110 227-239
• 12 Gwynne JT, Strauss III JF. The role of lipoprotein in steroidogenesis and cholesterol metabolism in steroidogenic glands.  Endocr Rev. 1982;  3 299-329
• 13 Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins.  Lancet. 2002;  359 2195-2198
• 14 Jay RH, Sturley RH, Stirling C, MacGarrigle HH, Katz M, Reckless JP, Betteridge DJ. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolemia.  Br J Clin Pharmacol. 1991;  32 417-422
• 15 LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Treating to New Targets (TNT) Investigators . Intensive lipid lowering with atorvastatin in patients with stable coronary disease.  N Engl J Med. 2005;  352 1425-1435
• 16 Purvis K, Tollefsrud A, Rui H, Haug E, Norseth J, Viksmoen L, Ose L, Lund H. Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolaemia.  Eur J Clin Pharmacol. 1992;  42 61-64
• 17 Santini SA, Carrozza C, Lulli P, Zuppi C, CarloTonolo G, Musumeci S. Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.  J Atheroscler Thromb. 2003;  10 160-164
• 18 Travia D, Tosi F, Negri C, Faccini G, Moghetti P, Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads.  J Clin Endocrinol Metab. 1995;  80 836-840
• 19 Tureck RW, Strauss III JF. Progesterone synthesis by luteinized human granulosa cells in culture: the role of de novo sterol synthesis and lipoprotein-carried sterol.  J Clin Endocrinol Metab. 1982;  54 367-373

Correspondence